Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewFibroblast growth factor 21: from pharmacology to physiologyTraditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice.Identification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated ReceptorsIdentification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetesShort-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γNr4a1 is required for fasting-induced down-regulation of Pparγ2 in white adipose tissue.A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesSelective Tissue Distribution Mediates Tissue-Dependent PPARγ Activation and Insulin Sensitization by INT131, a Selective PPARγ Modulator.PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesisDiscovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic DrugsSelective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivityThe role of adiponectin in cancer: a review of current evidence.MED25 is a mediator component of HNF4α-driven transcription leading to insulin secretion in pancreatic beta-cells.Feed-forward transcriptional programming by nuclear receptors: regulatory principles and therapeutic implicationsTherapeutic targets for treating fibrotic kidney diseasesPeroxisome proliferator-activated receptor γ controls ingestive behavior, agouti-related protein, and neuropeptide Y mRNA in the arcuate hypothalamus.Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanismsPharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.Pharmacological repression of PPARγ promotes osteogenesisPhysiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone.Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosisNutraceuticals as Ligands of PPARγRegulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Safety of Anti-Diabetic Therapies on Bone.In vitro Screening and Evaluation of 37 Traditional Chinese Medicines for Their Potential to Activate Peroxisome Proliferator-Activated Receptors-γ.SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism.Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospectiveCandesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model.Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage PolarizationIdentification of PPARγ ligands with One-dimensional Drug Profile Matching.PPARγ signaling and metabolism: the good, the bad and the future.Adiponectin in insulin resistance: lessons from translational research.Targeting nuclear receptors with marine natural products.
P2860
Q24561401-309FE8E1-78D9-4BD9-849E-00AF6714EDF5Q24658126-8C8C3F4A-4A69-4E10-AE4A-99CCE024E365Q27309112-051C4B08-2586-4761-B8B0-275B925A1498Q27675297-9FFBA06F-8E27-43C1-91D7-1DD47A071B35Q27683508-AF8FF436-4796-4532-83E3-FD2F69687DAAQ30538765-8CD71823-9E9D-415E-B602-D1DE7DE094BCQ33636236-088D2AA0-A06E-4DC2-8D49-B0CA605D1EA1Q33637862-42C75FD4-DD8D-46E2-B847-352A6136C573Q33736617-84590BF0-333C-4CF0-88EA-BEB05E495541Q33745028-2384F813-B126-45C6-A43D-8EC9A18D4C5BQ33808884-BF9348AD-894E-4311-B0F0-C925D36C7ADDQ33809886-E3C6691D-A112-421A-A5DF-1B8B06226166Q33976093-EC18E0DB-A01B-45B6-8965-382B626B99E3Q34067485-E92CAE4E-A5E1-4799-8E00-75B4D790F900Q34161200-0D69D9A8-FB4F-4364-8B0C-11B6BB4B10D3Q34235817-EDBB7B25-81EA-4F0D-B3B9-FD2BDFBEBDD7Q34249161-553D9A69-10E6-4933-BB38-DFBD11008358Q34271986-18980DB4-B552-4746-B16F-7E224A63C28EQ34406080-99059E9E-A798-45ED-AD16-0AC04F8F7A38Q35067776-4F305E94-2D45-4002-B614-BA58449D4A1AQ35079607-AEF2D03C-7A34-4280-A8D0-276E4CD9E68FQ35187442-4259B1F4-A67A-40A3-95E7-A6D60B8B12DAQ35274791-CC2FC452-9279-4085-9BFB-170DA593391CQ35395528-273A37C7-227B-4810-BD8B-4771C03FE37BQ35754510-DCF15ACD-4905-4DB8-A908-71F7614349B1Q35762720-9A9EBA23-E622-48D8-A4DA-D9FD5E851CDCQ35860302-19CCC84E-6DB5-4DF8-AC73-EE134D6962B2Q35954579-A357D579-FA26-46B7-94A6-486D98066BEFQ36072211-61F5D729-7A2A-4780-B32F-0CE1509CE9E3Q36093802-3DA9795C-AC7D-4B0C-A1A8-BEBFD6B80F44Q36716222-67B1D952-A39E-45C9-8591-86B94A872440Q36733126-0A0DF155-75DD-423A-BEBE-2F53A67F7BAFQ36760160-82D9D2F6-F8F4-4D7C-A572-BA4D4CDFEC7EQ36814812-62763D8E-54C9-4C9C-8900-E0B0F838C9CAQ37001374-D6005D0F-9D56-48D7-9E66-C789B596D620Q37149978-27284E62-00BB-4251-A481-9CC60C405902Q37165170-B47C1F41-3B80-4F5A-80C0-297482AFF0CDQ37407887-632E86A9-0DC2-42CF-845A-2EBE71C9105EQ37474736-8010CAF4-137C-4A80-A569-4B0129499F13Q37621100-1DFA0D67-1818-472E-A5B1-A9FC380C79CD
P2860
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Selective peroxisome prolifera ...... rapeutic PPARgamma activation.
@en
Selective peroxisome proliferator-activated receptor gamma
@nl
type
label
Selective peroxisome prolifera ...... rapeutic PPARgamma activation.
@en
Selective peroxisome proliferator-activated receptor gamma
@nl
prefLabel
Selective peroxisome prolifera ...... rapeutic PPARgamma activation.
@en
Selective peroxisome proliferator-activated receptor gamma
@nl
P356
P1476
Selective peroxisome prolifera ...... rapeutic PPARgamma activation.
@en
P2093
Alex M Depaoli
Linda Slanec Higgins
P304
P356
10.3945/AJCN.2009.28449E
P407
P577
2009-11-11T00:00:00Z